Lung Cancer

Merck and Gilead report mixed outcomes in lung cancer and HIV studies

Merck Gilead report mixed outcomes in key lung cancer and HIV studies: a Phase 3 Trodelvy plus KEYTRUDA lung cancer trial was halted, while two Phase 3 HIV studies for islatravir/lenacapavir reported positive topline results. This plan focuses on the business and clinical implications for analysts and BD teams.

EMA backs datopotamab deruxtecan, but lung cancer access remains unclear

EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.

FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label

The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.

FDA clears U.S. trial of MAIA lung cancer drug for third-line patients

The FDA has cleared MAIA Biotechnology to open U.S. enrollment in the expanded Phase 2 THIO-101 trial of ateganosine for third-line non-small cell lung cancer. This milestone, combined with Fast Track designation, positions MAIA for potential Accelerated Approval and shifts the competitive landscape in late-line NSCLC.

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

Antibody-drug conjugates (ADCs) represent a novel class of therapeutics that selectively target tumor cells and deliver concentrated cytotoxic payloads, showing significant antitumor activity in lung cancer. This analysis covers the latest evidence, key targets, and strategic implications for BD teams, investors, and analysts.

Roche's Alecensa Secures Expanded Approval in Japan for ALK-Positive Lung Cancer

Roche has secured an expanded approval for Alecensa in Japan, broadening its therapeutic reach for patients with ALK-positive non-small cell lung cancer. This development underscores Roche's commitment to advancing targeted therapies in oncology.

Ivonescimab HARMONi-6 Lung Cancer Survival

Akeso and Summit's recent lung cancer trial results indicate significant survival benefits. This article explores the implications for the pharmaceutical industry.